echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of the State Food and Drug Administration on Revising the Instructions for Carbimazole Tablets (No. 80 of 2021)

    Announcement of the State Food and Drug Administration on Revising the Instructions for Carbimazole Tablets (No. 80 of 2021)

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the evaluation results of adverse drug reactions, in order to further ensure the safety of public use of drugs, the National Medical Products Administration has decided to make unified revisions to the instructions of Carbimazole Tablets [Adverse Reactions], [Contraindications], [Precautions] and other items
    .
    The relevant matters are hereby announced as follows: 1.
    The marketing authorization holders of the above-mentioned drugs shall revise the instructions (see appendix) in accordance with the relevant provisions of the "Administrative Measures for Drug Registration" and other relevant regulations, and report to the provincial level before September 8, 2021 Recorded by the drug supervision and administration department
    .
    If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
    .
    Drugs produced on the date of filing shall not continue to use the original drug instructions
    .
    The holder of the drug marketing authorization shall replace the instructions and labels of the drugs that have been shipped out of the factory within 9 months after filing
    .
    2.
    The drug marketing license holder shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on drug use and safety issues, and instruct physicians, pharmacists or patients to use drugs rationally
    .
    3.
    Clinicians and pharmacists should carefully read the revised contents of the above-mentioned drug inserts, and when choosing medications, they should conduct a sufficient benefit/risk analysis based on the newly revised inserts
    .
    4.
    The patient should read the drug insert carefully before taking the medicine, and strictly follow the doctor's prescription
    .
    5.
    The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law
    .
    Hereby announce
    .
    Attachment: Requirements for the revision of the instructions for Carbimazole Tablets National Medical Products Administration June 9, 2021 National Medical Products Administration Announcement No.
    80, 2021 Annex.
    docx
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.